Contrasting AVEO Pharmaceuticals (AVEO) & Its Competitors
AVEO Pharmaceuticals (NASDAQ: AVEO) is one of 282 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare AVEO Pharmaceuticals to related companies based on the strength of its dividends, analyst recommendations, earnings, risk, profitability, institutional ownership and valuation.
Valuation & Earnings
This table compares AVEO Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|AVEO Pharmaceuticals||$2.52 million||-$26.88 million||-4.18|
|AVEO Pharmaceuticals Competitors||$288.06 million||$35.21 million||147.92|
AVEO Pharmaceuticals’ competitors have higher revenue and earnings than AVEO Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares AVEO Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AVEO Pharmaceuticals Competitors||-5,295.65%||-475.57%||-39.68%|
This is a summary of recent ratings and recommmendations for AVEO Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AVEO Pharmaceuticals Competitors||794||3142||11417||229||2.71|
AVEO Pharmaceuticals presently has a consensus price target of $4.17, suggesting a potential upside of 40.29%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.22%. Given AVEO Pharmaceuticals’ competitors higher probable upside, analysts clearly believe AVEO Pharmaceuticals has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
53.9% of AVEO Pharmaceuticals shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.7% of AVEO Pharmaceuticals shares are held by insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
AVEO Pharmaceuticals has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, AVEO Pharmaceuticals’ competitors have a beta of 6.11, suggesting that their average share price is 511% more volatile than the S&P 500.
AVEO Pharmaceuticals competitors beat AVEO Pharmaceuticals on 8 of the 12 factors compared.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.